HPV vaccine study for women with HPV16
Treatments studied
Part of Infections clinical trials.
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 to 45
- Must have tested positive for HPV16 (with or without other HPV types)
- No current or recent (last 12 months) genital warts or lesions needing treatment
- Never received an HPV vaccine before
- Not pregnant and willing to use birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether getting the HPV vaccine after treatment for vulvar high-grade lesions can help prevent the lesions from coming back. It is for women who have not been vaccinated before and are about to have treatment for this condition.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
This trial aims to develop a vaccine that trains your immune system to fight HPV, the virus that causes cervical cancer. By studying your blood, researchers hope to find better ways to prevent the cancer from coming back.
This trial tests an experimental vaccine for women who have HPV type 16 but only mild or no precancerous changes (CIN1 or less). The vaccine uses a special device to help your body's immune system fight the virus, which may prevent it from becoming cervical cancer.
Hear when a new Human Papilloma Virus Infection Type 16 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.